Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Zhendong Chen"'
Autor:
Guisheng Li, Qiong Wu, Jin Li, Xiuwen Wang, Yiye Wan, Ying Cheng, Jianping Xiong, Chunhong Hu, Jianqiang Cai, Yong-Qiang Li, Yong Tang, Helong Zhang, Jiang liu, Baoli Qin, Jifeng Feng, Jian Dong, Jianfeng Zhou, Yongqian Shu, Xingwen Li, Jianhong Wang, Yongkun Sun, Minhui Wu, Yigui Chen, Nong Xu, Zhendong Chen, Yuxian Bai, Jufeng Wang, Yanhong Deng, Da Jiang, Yi Ba, Chengxue Dang, Yujuan Qi, Jianming Xu, Donglin Wang, Yihebali Chi
Publikováno v:
Oncologist
Background Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for patients with refra
Autor:
Qingyuan Zhang, Zhimin Shao, Yiqun Han, Quchang Ouyang, Cuizhi Geng, Shanshan Chen, Jiayu Wang, Hui Li, Shune Yang, Hong Liu, Binghe Xu, Sanyuan Sun, Jianguo Lu, Zhendong Chen, Junguo Lu, Jianwei Sun, Jingfen Wang, Haixin Huang
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Background To evaluate the efficacy and safety of recombinant human serum albumin /granulocyte colony-stimulating factor (rHSA/G-CSF) in breast cancer following receipt of cytotoxic agents. Methods The phase 1b trial assessed the pharmacokinetics, ph
Autor:
Qingxia Fan, Shukui Qin, Xianbao Zhan, Ming Zeng, Yong Gao, Chen Yun, Kangsheng Gu, Dong Ma, Helong Zhang, Jing Huang, Tao Zhang, Jianhua Chen, Jia Chen, Lei Chen, Tianshu Liu, Zhanhui Miao, Zhendong Chen, Enxiao Li, Zhichao Fu, Jianming Xu, Lu Gan, Jianping Xiong, Ying Yuan, Gang Wu, Zuoxing Niu, Qing Yang, Jianjun Zou, Nong Xu, Li Zhang, Yueyin Pan, Zhiping Li, Yi Ba, Suxia Luo, Jun Wang, Yuxian Bai, H. Lu, Yongqian Shu, Yi Hu, Feng Peng, Xiaodong Jiang, Ying Liu, Yiping Zhang, Lin Shen, Lin Zhao, Lizhu Lin, Wu Zhuang, Wei Ren
Publikováno v:
The Lancet. Oncology. 21(6)
Summary Background Patients with advanced or metastatic oesophageal squamous cell carcinoma have poor prognosis and few treatment options after first-line therapy. We aimed to assess efficacy and safety of the anti-PD-1 antibody camrelizumab versus i
Autor:
Jifeng Feng, Yu Shen, Xuhong Min, Teng Mao, Ying Cheng, Qingxia Fan, Li Zhang, Dong Wang, Kangsheng Gu, Escort st Investigators, Helong Zhang, Jiancheng Li, Jun Wang, Ying Liu, Jing Huang, Zhihua Liu, Yiping Zhang, Jin Lu, Kuaile Zhao, Zou Jian-Jun, Qing Yang, Zhendong Chen, Rui-Hua Xu, Huiyan Luo, Yuxian Bai, Yi Ba, Zuoxing Niu, Zhichao Fu, Lin Wu, Shegan Gao, Xiaodong Zhang
Publikováno v:
JAMA. 326:916
Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced o
Autor:
Shiying Yu, Yiping Zhang, Binghe Xu, K. Gu, Junlan Yang, Fengchun Zhang, Zefei Jiang, Chuan Wang, Zhimin Shao, Shuping Song, Jifeng Feng, Jiayu Wang, Zhendong Chen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:223-230
Fulvestrant, an oestrogen receptor (ER) antagonist with no known agonist effects, has shown activity in postmenopausal patients with ER-positive advanced breast cancer recurring or progressing following prior endocrine therapy. This double-blind, dou
Autor:
Jessie Zou, Yoon-Koo Kang, Jiwei Liu, Chao Jung Tsao, Ann-Lii Cheng, Jun Suk Kim, Karin Burock, Jiejun Wang, Houjie Liang, Rongcheng Luo, Jianming Xu, Shukui Qin, Zhongzhen Guan, Jifeng Feng, Yan Sun, D. Voliotis, Sheng-Long Ye, Hongming Pan, Tsai Sheng Yang, Zhendong Chen, Won Young Tak
Publikováno v:
The Lancet Oncology. 10:25-34
Summary Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific popul
Autor:
John S. Bomalaski, Yee Chao, Li-Tzong Chen, Francesco Izzo, Debashis Sarker, Ghassan K. Abou-Alfa, Luigi Bolondi, Richard A Hubner, Sheng-Nan Lu, Massimo Colombo, Baek-Yeol Ryoo, Yin-Hsun Feng, William P. Harris, Chen-Chun Lin, Ho Yeong Lim, Zhendong Chen, Gina M. Vaccaro, Tim Meyer, Chia Jui Yen, Shukui Qin
Publikováno v:
Journal of Clinical Oncology. 34:4017-4017
4017Background: Arginine (Ar) depletion is a putative target in HCC, which lacks the citrulline (Ci) to Ar repleting enzyme argininosuccinate synthetase. A is an Ar degrading enzyme cloned from M. ...